Extent of attaining and maintaining symptom remission by antipsychotic medication in the treatment of chronic schizophrenia: Evidence from the CATIE study

Schizophrenia Research

Volumn 133, Issue 1-3, 2011, Pages 42-46

  Levine, Stephen Z ^a   Rabinowitz, Jonathan ^a   Ascher Svanum, Haya ^b   Faries, Douglas E ^b   Lawson, Anthony H ^b  

^a BAR ILAN UNIVERSITY   (Israel)

^b ELI LILLY AND COMPANY   (United States)

Author keywords

Antipsychotic medication; CATIE; Clinical trial; Remission; Schizophrenia

Indexed keywords

NEUROLEPTIC AGENT; OLANZAPINE; PERPHENAZINE; QUETIAPINE; RISPERIDONE; ZIPRASIDONE;

ARTICLE; CONTROLLED STUDY; DRUG DOSE COMPARISON; DRUG EFFICACY; EVIDENCE BASED MEDICINE; FOLLOW UP; HUMAN; MAJOR CLINICAL STUDY; NATIONAL HEALTH ORGANIZATION; OUTCOME ASSESSMENT; PHASE 1 CLINICAL TRIAL (TOPIC); POSITIVE AND NEGATIVE SYNDROME SCALE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); REMISSION; SCHIZOPHRENIA; SENSITIVITY ANALYSIS; SYMPTOM; TREATMENT DURATION;

ANTIPSYCHOTIC AGENTS; DOUBLE-BLIND METHOD; FEMALE; FOLLOW-UP STUDIES; HUMANS; MALE; PATIENT COMPLIANCE; PSYCHIATRIC STATUS RATING SCALES; RECURRENCE; SCHIZOPHRENIA; SCHIZOPHRENIC PSYCHOLOGY; SENSITIVITY AND SPECIFICITY; TIME FACTORS; TREATMENT OUTCOME;

EID: 81955164231     PISSN: 09209964     EISSN: 15732509     Source Type: Journal    
DOI: 10.1016/j.schres.2011.09.018     Document Type: Article

References (17)

1. Andreasen N.C. Standardized remission criteria in schizophrenia. Acta Psychiatr. Scand. 2006, 113(2):81.
2. Andreasen N.C., Carpenter W.T., Kane J.M., Lasser R.A., Marder S.R., Weinberger D.R. Remission in schizophrenia: proposed criteria and rationale for consensus. Am. J. Psychiatry 2005, 162(3):441-449.
3. Emsley R., Rabinowitz J., Medori R. Remission in early psychosis: rates, predictors, and clinical and functional outcome correlates. Schizophr. Res. 2007, 89(1-3):129-139.
4. Hochberg Y. A sharper Bonferroni procedure for multiple tests of significance. Biometrika 1988, 75(4):800-802.
5. Kane J.M. An evidence-based strategy for remission in schizophrenia. Journal of Clinical Psychiatry 2008, 69:25-30.
6. Kay S.R., Fiszbein A., Opler L.A. The positive and negative syndrome scale (PANSS) for schizophrenia. Schizophr. Bull. 1987, 13(2):261-276.
7. Keefe R.S., Bilder R.M., Davis S.M., Harvey P.D., Palmer B.W., Gold J.M. Neurocognitive effects of antipsychotic medications in patients with chronic schizophrenia in the CATIE Trial. Arch. Gen. Psychiatry 2007, 64(6):633-647.
8. Leucht S., Corves C., Arbter D., Engel R.R., Li C., Davis J.M. Second-generation versus first-generation antipsychotic drugs for schizophrenia: a meta-analysis. Lancet 2009, 373(9657):31-41.
9. Leucht S., Davis J.M., Engel R.R., Kissling W., Kane J.M. Definitions of response and remission in schizophrenia: recommendations for their use and their presentation. Acta Psychiatr. Scand. 2009, (438):7-14. Suppl.
10. Leucht S., Komossa K., Rummel-Kluge C., Corves C., Hunger H., Schmid F. A meta-analysis of head-to-head comparisons of second-generation antipsychotics in the treatment of schizophrenia. Am. J. Psychiatry 2009, 166(2):152-163.
11. Lieberman J.A., Stroup T.S., McEvoy J.P., Swartz M.S., Rosenheck R.A., Perkins D.O. Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. N. Engl. J. Med. 2005, 353(12):1209-1223.
12. McEvoy J.P., Lieberman J.A., Stroup T.S., Davis S.M., Meltzer H.Y., Rosenheck R.A. Effectiveness of clozapine versus olanzapine, quetiapine, and risperidone in patients with chronic schizophrenia who did not respond to prior atypical antipsychotic treatment. Am. J. Psychiatry 2006, 163(4):600-610.
13. Rosenheck R.A., Leslie D.L., Sindelar J., Miller E.A., Lin H., Stroup T.S. Cost-effectiveness of second-generation antipsychotics and perphenazine in a randomized trial of treatment for chronic schizophrenia. Am. J. Psychiatry 2006, 163(12):2080-2089.
14. Stroup T.S., McEvoy J.P., Swartz M.S., Byerly M.J., Glick I.D., Canive J.M. The National Institute of Mental Health Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) project: schizophrenia trial design and protocol development. Schizophr. Bull. 2003, 29(1):15-31.
15. Stroup T.S., Lieberman J.A., McEvoy J.P., Swartz M.S., Davis S.M., Rosenheck R.A. Effectiveness of olanzapine, quetiapine, risperidone, and ziprasidone in patients with chronic schizophrenia following discontinuation of a previous atypical antipsychotic. Am. J. Psychiatry 2006, 163(4):611-622.
16. Stroup T.S., Lieberman J.A., McEvoy J.P., Swartz M.S., Davis S.M., Capuano G.A. Effectiveness of olanzapine, quetiapine, and risperidone in patients with chronic schizophrenia after discontinuing perphenazine: a CATIE study. Am. J. Psychiatry 2007, 164(3):415-427.
17. Stroup T.S., Lieberman J.A., McEvoy J.P., Davis S.M., Swartz M.S., Keefe R.S. Results of phase 3 of the CATIE schizophrenia trial. Schizophr. Res. 2009, 107(1):1-12.